Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?

被引：117

作者：

Welsh, Paul ^{[2
]}

Grassia, Gianluca ^{[1
]}

Botha, Shani ^{[3
]}

Sattar, Naveed ^{[2
]}

Maffia, Pasquale ^{[1
,2
,4
]}

机构：

[1] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun &, Ctr Immunobiol, Glasgow, Lanark, Scotland

[2] Univ Glasgow, Coll Med Vet & Life Sci, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland

[3] North West Univ, Potchefstroom Campus, Potchefstroom, South Africa

[4] Univ Naples Federico II, Dept Pharm, Naples, Italy

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2017年 / 174卷 / 22期

基金：

英国工程与自然科学研究理事会;

关键词：

C-REACTIVE PROTEIN; TUMOR-NECROSIS-FACTOR; CORONARY-HEART-DISEASE; SECRETORY PHOSPHOLIPASE A(2); INTERLEUKIN-1 RECEPTOR ANTAGONIST; APPARENTLY HEALTHY-MEN; SMOOTH-MUSCLE-CELLS; RHEUMATOID-ARTHRITIS; ASCORBIC-ACID; FACTOR-ALPHA;

D O I：

10.1111/bph.13818

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Data from basic science experiments is overwhelmingly supportive of the causal role of immune-inflammatory response(s) at the core of atherosclerosis, and therefore, the theoretical potential to manipulate the inflammatory response to prevent cardiovascular events. However, extrapolation to humans requires care and we still lack definitive evidence to show that interfering in immune-inflammatory processes may safely lessen clinical atherosclerosis. In this review, we discuss key therapeutic targets in the treatment of vascular inflammation, placing basic research in a wider clinical perspective, as well as identifying outstanding questions.

引用

页码：3898 / 3913

页数：16

共 50 条

[1] Targeting inflammation to reduce cardiovascular disease risk
Maffia, Pasquale
Cirino, Giuseppe
BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 (22) : 3895 - 3897
[2] Targeting Inflammation to Reduce Residual Cardiovascular Risk
Ajala, Oluremi N.
Everett, Brendan M.
CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (11)
[3] Targeting Inflammation to Reduce Residual Cardiovascular Risk
Oluremi N. Ajala
Brendan M. Everett
Current Atherosclerosis Reports, 2020, 22
[4] Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection
Titanji, Boghuma
Gavegnano, Christina
Hsue, Priscilla
Schinazi, Raymond
Marconi, Vincent C.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (03):
[5] Targeting Inflammation in Cardiovascular Disease
Deftereos, Spyridon
Bouras, Georgios
MEDICINAL CHEMISTRY, 2014, 10 (07) : 641 - 642
[6] Targeting Lipoprotein(a) to reduce residual risk in high risk atherosclerotic cardiovascular disease patients
Waring, Ashley A.
Morris, Pamela B.
REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2023, 52 (02): : 59 - 64
[7] IS IT ENOUGH JUST TO TREAT INFLAMMATION TO REDUCE CARDIOVASCULAR RISK?
Nurmohamed, M. T.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 5 - 5
[8] Cardiovascular Risk Reduction in Patients With Chronic Kidney Disease Potential for Targeting Inflammation With Canakinumab
Cherney, David Z. I.
Lytvyn, Yuliya
McCullough, Peter A.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (21) : 2415 - 2418
[9] Inflammation, glucocorticoids and risk of cardiovascular disease
Buttgereit, Frank
Burmester, Gerd-Ruediger
Lipworth, Brian J.
NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2009, 5 (01): : 18 - 19
[10] Inflammation, aspirin, and the risk of cardiovascular disease
Bruno, JJ
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (06): : 422 - 422

← 1 2 3 4 5 →